pH/ROS 双响应式自放大式 ROS 补充式自递送系统用于瘤特异化疗/费罗普托सिस
Xiaomei Zhao1, Ruonan Zhao1, Peng Liu1
1State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China.
Bioconjugate chemistry
|November 18, 2025
概括
这项研究开发了用于癌症治疗的双响应纳米粒子. 这些纳米颗粒通过放大活性氧物种 (ROS) 和释放化疗剂,特别是在瘤中,有效地输送药物.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 在瘤学瘤学.
背景情况:
- 瘤微环境 (TME) 具有异质的活性氧物种 (ROS) 水平,限制了传统的ROS响应药物递送系统 (DDS).
- 需要有针对性的疗法来克服TME的局限性,并提高治疗疗效.
研究的目的:
- 为增强癌症治疗设计一种pH/ROS双响应的两性共聚药物纳米粒子 (NP).
- 调查TME中自我放大降解和药物释放机制.
- 评估协同化学和铁灭的治疗效果.
主要方法:
- 合成的P ((CA-DOX-Fc) -PEG共聚合物和自组装成纳米粒子 (P ((CA-DOX-Fc) -PEG-NPs).
- 在各种条件下表征NP稳定性,药物加载和释放动力学.
- 研究了由谷氨 (GSH) 耗尽和ROS升高引发的NP降解机制.
- 在HepG2细胞中评估了细胞吸收,体外细胞毒性和治疗协同作用.
主要成果:
- P ((CA-DOX-Fc) -PEG-NPs表现出高药含量,稳定性和最小的过早泄漏.
- 在酸性和氧化性TME条件下,双刺激反应使自我放大降解和增强多克索鲁比辛 (DOX) 释放成为可能.
- 在HepG2细胞中观察到DOX的有效细胞吸收和核积累.
- 在HepG2细胞中获得了低IC50 (8.91微克/毫升) 的协同化疗和铁化疗,在正常L02细胞中具有高活力 (CI=0.92).
结论:
- P(CA-DOX-Fc) -PEG-NP代表了精确,瘤特异性组合疗法的有前途的战略.
- 开发的NP有效地补充ROS,并实现环境触发的药物释放,以增强治疗效果.
- 这种方法为克服TME异质性和改善癌症治疗结果提供了一个新的平台.
更多相关视频
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.7K
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
1.8K
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...